Chris Raymond
Stock Analyst at Raymond James
(2.94)
# 1,373
Out of 5,154 analysts
9
Total ratings
66.67%
Success rate
55.76%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $55.80 | +120.43% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $34.56 | +30.21% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $34.54 | +1.33% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $100.13 | +4.86% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $9.68 | +137.73% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $37.46 | -19.91% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $10.31 | +627.45% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $55.80
Upside: +120.43%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $34.56
Upside: +30.21%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $34.54
Upside: +1.33%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $100.13
Upside: +4.86%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $9.68
Upside: +137.73%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $37.46
Upside: -19.91%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $10.31
Upside: +627.45%